All data are publically available with the exception of the microarray data. The DNA microarray data have not been made available for ethical reasons because they contain personal information on the study participants. Sequences have been deposited in Genbank (accession no. MH256127, MH256128, MH256129, MH256130, MH256131, MH256132, MH256133, MH256134, MH256135, MH256136).

Introduction {#sec001}
============

*Streptococcus pneumoniae* (the pneumococcus) is a Gram-positive pathogenic bacterium and a leading cause of community-acquired pneumonia \[[@pone.0206622.ref001]\]. Pneumococci are classified by serotype, defined by an antigenically-distinct polysaccharide capsule. Capsule biosynthesis is encoded by the capsular polysaccharide (*cps*) locus within the pneumococcal genome. High levels of genetic diversity within this locus has resulted in over 90 pneumococcal serotypes described to date.

The pneumococcal capsule is the target for currently licensed vaccines, which only include a subset of serotypes. Although pneumococcal conjugate vaccines (PCVs) have been successful in reducing carriage and disease caused by the targeted serotypes, a rise in carriage and disease caused by serotypes not included in these vaccines is commonly observed (serotype replacement) \[[@pone.0206622.ref002],[@pone.0206622.ref003]\]. To precisely monitor vaccine impact and disease surveillance, accurate tools for pneumococcal serotyping are required.

Molecular approaches to serotyping pneumococci rely on existing knowledge of *cps* loci. Data on pneumococcal *cps* loci from low- and middle-income countries (LMICs) are relatively limited, which can impact serotyping results. For example, we recently described a novel genetic variant of pneumococcal serotype 11A in Fiji. Genetically, the *cps* locus of these isolates is most closely related to the 11F *cps* locus, with only a few minor nucleotide changes resulting in the production of 11A capsule \[[@pone.0206622.ref004]\].

Among the replacing serotypes post-PCV introduction, serotype 33F has become a concern world-wide. Serotype 33F is commonly reported among the predominant serotypes not included in PCVs causing invasive disease following vaccine introduction \[[@pone.0206622.ref005]--[@pone.0206622.ref007]\]. The increased invasive disease caused by serotype 33F has warranted its inclusion in two new vaccine formulations, which are in development by Merck \[[@pone.0206622.ref008]\]. In this study, we describe a novel 33F *cps* locus identified in Fiji and Mongolia by investigating the genetic basis of the variation in this locus and the potential impact this may have on serotyping results.

Materials and methods {#sec002}
=====================

Nasopharyngeal swab collection and screening for pneumococci {#sec003}
------------------------------------------------------------

As part of ongoing programs in the Asia-Pacific region measuring pneumococcal vaccine impact, nasopharyngeal swabs from healthy participants in Fiji, and children diagnosed with pneumonia in Mongolia were collected in accordance with WHO recommendations \[[@pone.0206622.ref009]\]. Ethical approval for the study in Fiji was granted from the Fiji National Research ethics review committee and The University of Melbourne Human research ethics committee. Ethical approval for the study in Mongolia was granted from the ethics committee associated with The Ministry of Health in Mongolia and the Royal Children's Hospital in Melbourne. Written consent for study participants was provided by parents/guardians. Following collection, the swabs were placed in 1 ml skim milk, tryptone, glucose, and glycerol media \[[@pone.0206622.ref010]\] and stored at -80°C. Samples were screened for the presence of pneumococci by conducting quantitative PCR (qPCR) on DNA extracted from 100 μl aliquots of the swabs using the pneumococcal *lytA* gene as a target as previously described \[[@pone.0206622.ref011]\].

Molecular serotyping by microarray {#sec004}
----------------------------------

Molecular serotyping of pneumococci was performed by DNA microarray. An aliquot of the nasopharyngeal swab was inoculated onto Horse Blood Agar supplemented with gentamicin (5 μg/ml), to select for pneumococci, and incubated overnight at 37°C with 5% CO~2~. For plates with α-hemolytic growth, the bacterial growth was collected using 1 ml PBS, pelleted by centrifugation and stored at -30°C. DNA was extracted from thawed bacterial pellets using the QIAcube HT with the QIAamp 96 DNA QIAcube HT Kit (Qiagen) with the inclusion of a pre-treatment lysis step whereby 180 μl lysis buffer (20 mM TrisHCl, 2 mM EDTA, 1% Triton X-100, 2 mg/ml RNase A, 20 mg/ml lysozyme) was added to the bacterial pellet and incubated at 37ºC for 60 min. The remaining extraction procedure was as per the manufacturer's instructions. This DNA was then used for microarray as described previously \[[@pone.0206622.ref012]\]. In brief, 200 ng of DNA was labelled with Cy3 or Cy5 using the Genomic DNA ULS Labeling Kit (Agilent Technologies) and incubated at 85°C for 30 min. The labelled pneumococcal DNA was incubated with Senti-SPv1.5 microarray slides (BUGS Bioscience) overnight at 65°C rotating at 20 rpm. Microarray slides were washed, scanned, and analyzed using the Agilent microarray scanner and feature extraction software. Serotype calls were analyzed by Senti-NET software (BUGS Bioscience) using Bayesian-based algorithms.

Bacterial isolates {#sec005}
------------------

The *S*. *pneumoniae* isolates used in this study were purified from ten nasopharyngeal swabs containing 33F-1 from Fiji and Mongolia on selective media as described above. Isolates were confirmed as *S*. *pneumoniae* with microarray and whole genome sequencing.

Whole genome sequencing and molecular typing {#sec006}
--------------------------------------------

For whole genome sequencing, DNA was extracted from pure cultures using the Wizard SV genomic DNA purification system (Promega) with some modifications. Briefly, pneumococcal cultures were pre-treated with a lysis solution containing 5 mM EDTA, 3 mg/ml lysozyme and 37.5 μg/ml mutanolysin in TE buffer and incubated at 37°C for 2 h. Proteinase K was added to a final concentration of 1 mg/ml and samples were incubated at 55°C for 1 h. Following incubation, 200 μl of nuclear lysis buffer and 5 μl of RNase (final concentration of 40 μg/ml) were added and samples were incubated at 80°C for 10 min. The remaining extraction procedure was performed as per the manufacturer's instructions. Eluted DNA was sequenced in 2 x 300 bp paired end reads on the MiSeq platform. Using the Geneious 11.0.4 software package \[[@pone.0206622.ref013]\], sequence reads were trimmed with BBDuk and *de novo* assembled using SPAdes. The capsule loci were annotated within Geneious using a database consisting of capsule loci from the 90 serotypes described by Bentley et al. \[[@pone.0206622.ref014]\]. Sequence reads were also used for molecular typing with PneumoCaT \[[@pone.0206622.ref015]\].

Sequence analysis {#sec007}
-----------------

Pairwise alignments were using either MUSCLE or Clustal Omega. Phylogenetic analyses were performed for each 33F-1 *cps* gene using MEGA 7 \[[@pone.0206622.ref016]\]. For each gene, the phylogenetic analysis included a representative 33F-1 sequence as well as homologues from all other serotypes containing that gene as described by Bentley et al. \[[@pone.0206622.ref014]\], where Genbank accession numbers are provided. DNA sequences were aligned using MUSCLE and the alignments were used to generate maximum likelihood trees based on the Tamura-Nei model. Phylogenetic relationships were statistically analyzed by bootstrapping (1000 replicates). The 33F-1 *cps* loci have been deposited in Genbank (accession no. MH256127, MH256128, MH256129, MH256130, MH256131, MH256132, MH256133, MH256134, MH256135, MH256136).

Quellung and latex agglutination serotyping {#sec008}
-------------------------------------------

Quellung serotyping was performed as described previously \[[@pone.0206622.ref017]\]. A saline suspension of pneumococci was prepared from an overnight culture. Using an inoculation loop, 1 μl was placed on a microscope slide and mixed with 1 μl of antisera from the Statens Serum Institut (SSI) (<http://www.ssi.dk/ssidiagnostica>). The sample was then viewed under the microscope (x400 magnification). A positive reaction was defined as an enlargement or 'swelling' of cells, with serotype call based on the reaction profile with each typing sera. For latex agglutination, latex reagents were prepared with SSI typing sera \[[@pone.0206622.ref018]\] and testing performed as previously described \[[@pone.0206622.ref019]\]. The bacterial suspension and latex reagent (10 μl of each) were mixed on a glass slide. The slide was then incubated on an orbital shaker for 2 min at \~140 rpm. A positive reaction was defined by the presence of visible agglutination. The SSI factor sera used for serotyping of 33F-1 and 33F strains were 33b, 33e, 33f, 6a and 20b.

Results {#sec009}
=======

In our studies evaluating pneumococcal vaccine impact in Fiji and Mongolia, we have used DNA microarray as a molecular approach to serotype pneumococci contained within nasopharyngeal swabs. DNA microarray uses 15,000 oligonucleotides that are spotted onto glass slides and recognize each capsule gene from the 90+ serotypes. Labelled pneumococcal DNA is allowed to hybridize to the oligonucleotides so that pneumococcal serotype can be inferred. From 2750 swabs that contained pneumococci 25 (0.9%) contained pneumococci that typed as '33F-like' (hereby referred to as '33F-1'). Ten of these samples were selected and the 33F-1 pneumococci were isolated for further analysis ([Table 1](#pone.0206622.t001){ref-type="table"}).

10.1371/journal.pone.0206622.t001

###### Pneumococcal 33F-1 isolates used in this study.

![](pone.0206622.t001){#pone.0206622.t001g}

                                                                          MLST                               
  --------- -------------------------------------------------- ---------- ------ ---- --- ---- ---- ---- --- ---------------------------------------------
  PMP1348   Nasopharynx of healthy child (2--7 years old)      Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1349   Nasopharynx of healthy child (5--8 weeks old)      Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1351   Nasopharynx of healthy child (12--23 months old)   Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1352   Nasopharynx of healthy child (12--23 months old)   Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1353   Nasopharynx of healthy child (5--8 weeks old)      Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1379   Nasopharynx of healthy child (12--23 months old)   Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1380   Nasopharynx of healthy child (12--23 months old)   Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1383   Nasopharynx of healthy adult                       Fiji       2      18   5   23   18   42   3   13802[^a^](#t001fn001){ref-type="table-fn"}
  PMP1386   Nasopharynx of child with pneumonia                Mongolia   2      18   5   29   16   42   3   673
  PMP1387   Nasopharynx of child with pneumonia                Mongolia   2      18   5   29   16   42   3   673

^a^Novel sequence type identified in this study.

Compared to the expected results for serotype 33F, microarray reported the *wciG*, *glf* and *wcjE* genes in the nasopharyngeal swabs containing these isolates as 'absent/divergent'. In addition, the *wcyO* gene was also detected, which has not been reported in the serotype 33F *cps* locus previously. To investigate the impact of the divergent 33F-1 *cps* locus on other molecular approaches to serotyping, we sequenced the genomes of all ten isolates and ran the sequence reads through the PneumoCaT pipeline \[[@pone.0206622.ref015]\]. PneumoCaT uses *wcjE* to differentiate 33A from 33F, as this gene contains a frameshift mutation in 33F, resulting in a lack of WcjE-mediated O-acetylation of the 33F capsular polysaccharide \[[@pone.0206622.ref020]\]. Consistent with microarray, PneumoCaT typed all isolates as 33F and was unable to detect *wcjE*. Phenotypic serotyping methods (Quellung and latex agglutination) also typed these isolates as 33F ([S1 Table](#pone.0206622.s001){ref-type="supplementary-material"} and [S1 Fig](#pone.0206622.s003){ref-type="supplementary-material"}).

Following investigation of the 33F-1 *cps* locus, it was evident that not only did all ten isolates lack *wcjE*, the locus contained *wcyO* at this position. The *wcyO* gene encodes an acetyltransferase and mediates the same modification as *wcjE* (6-O-acetylation of galactose) \[[@pone.0206622.ref021]\]. The *wcyO* open reading frame from all 33F-1 isolates contained a frameshift mutation. The *wcyO* gene in 33F-1 pneumococci from Fiji had a single T insertion whereas this gene in isolates from Mongolia contained a single A deletion ([Fig 1](#pone.0206622.g001){ref-type="fig"}). These frameshift mutations were also confirmed by Sanger sequencing and were not present in traditional *wcyO-*containing isolates (serotypes 34 and 39) from Fiji ([S2 Fig](#pone.0206622.s004){ref-type="supplementary-material"}).

![Comparison of the *wcyO* open reading frames of 33F-1 sequences to a representative serotype 34 sequence.\
Only a selected portion of the DNA sequence is shown. Numbers refer to the position number in the serotype 34 sequence with an in-frame *wcyO* gene.](pone.0206622.g001){#pone.0206622.g001}

In addition to the differences in *wcjE* and *wcyO*, microarray detected some divergence in other genes in the 33F-1 *cps* locus compared to the reference 33F sequence. To gain a better understanding of the relationships of the 33F-1 *cps* genes to homologues from other serotypes we performed phylogenetic analyses for each gene. In support of the pairwise alignments ([S2 Table](#pone.0206622.s002){ref-type="supplementary-material"}), the 33F-1 *wciB*, *wciD*, *wciE*, *wciF*, *wzy* and *wzx* genes clustered with 37/33A/33F sequences ([Fig 2F and 2G](#pone.0206622.g002){ref-type="fig"} and [Fig 3A--3D](#pone.0206622.g003){ref-type="fig"}). In contrast, 33F-1 *wzg*, *wzh*, *wzd*, *wze* and *wchA* clustered with serotype 33B sequences ([Fig 2A--2E](#pone.0206622.g002){ref-type="fig"}), *wciG* with serotype 37 ([Fig 3E](#pone.0206622.g003){ref-type="fig"}), *glf* with serotypes 34 and 39 ([Fig 3F](#pone.0206622.g003){ref-type="fig"}) and *wcyO* with 33C, 34 and 39 ([Fig 3G](#pone.0206622.g003){ref-type="fig"}). All branches had strong statistical support (\>85% bootstrap score from 1000 replicates for all genes, except *wze* with a 67% bootstrap score for the 33F-1/33B branch).

![Maximum likelihood phylogenetic trees of 33F-1 *cps* genes (*wzg-wciD*) with homologues from all other serotypes.\
As all genes except *wchA* were identical in all 33F-1 isolates only one sequence is included as a representative. Un-collapsed trees are provided in [S5 Fig](#pone.0206622.s007){ref-type="supplementary-material"}. Tree for *wciC* is not shown as this gene is only present in serotypes 33F, 33A and 37, which all have over 98% DNA sequence identity to the 33F-1 sequence. DNA sequences were aligned using MUSCLE and trees were constructed using the Tamura-Nei model in MEGA 7. Only bootstrap values above 50% are shown.](pone.0206622.g002){#pone.0206622.g002}

![Maximum likelihood phylogenetic trees of 33F-1 *cps* genes (*wciE-wcyO*) with homologues from all other serotypes.\
As all genes except *wcyO* were identical in all 33F-1 isolates only one sequence is included as a representative. Un-collapsed trees are provided in [S5 Fig](#pone.0206622.s007){ref-type="supplementary-material"}. DNA sequences were aligned using MUSCLE and trees were constructed using the Tamura-Nei model in MEGA 7. Only bootstrap values above 50% are shown.](pone.0206622.g003){#pone.0206622.g003}

Discussion {#sec010}
==========

Pneumococcus is a highly successful pathogen, in part due to the high level of capsule diversity, resulting in over 90 serotypes each with unique antigenic properties. Even small differences in the *cps* locus can have biologically relevant consequences. Serotypes 33F and 33A have the same *cps* locus, except that 33F has a *wcjE* gene containing a frameshift mutation rendering it non-functional \[[@pone.0206622.ref022]\]. Using DNA microarray, we identified a high degree of genetic divergence in the capsule DNA sequence of some serotypes in Fiji and Mongolia. We characterized a serotype 33F variant (33F-1) that has the same genes as the canonical 33F and 33A *cps* loci, except it possesses *wcyO* instead of *wcjE*. Interestingly, in the 33F-1 variants *wcyO* is predicted to encode a truncated protein due to a frameshift mutation. These frameshift mutations suggest a loss of 6-O-acetylation in 33F-1 capsular polysaccharide as the truncated protein would unlikely be functional. Interestingly, the same variant has been simultaneously identified in the Global Pneumococcal Sequencing Project in other countries (van Tonder et al, unpublished), demonstrating 33F-1 pneumococci are not restricted to Fiji and Mongolia.

Although Quellung and latex agglutination serotyping supports the notion that the 33F-1 *cps* locus encodes a 33F capsule, it is important to note that sera used in these methods are polyclonal and there is potential for closely related serotypes to cross-react. In addition, the sera may not recognize all relevant epitopes in the capsule. Although there is no genetic difference that would result in an obvious antigenic change and no serological differences were detected in our study, we cannot eliminate the possibility that differences between 33F and 33F-1 capsules exist. Pairwise alignment of the amino acid sequences of 33F and 33F-1 capsular biosynthesis proteins showed high levels of similarity (over 96% identity for all proteins) ([S3 Fig](#pone.0206622.s005){ref-type="supplementary-material"}). The exceptions were the divergent WciG (85.2% identity) and Glf (94.6% identity). Despite reduced amino acid similarity of the 33F-1 WciG and Glf proteins to 33F homologues, we hypothesise that they would likely mediate the same modifications. This is supported in other serotypes where these enzymes have similar levels of variation but still perform the same function \[[@pone.0206622.ref014],[@pone.0206622.ref020]\].

The frameshift mutations in isolates from Fiji and Mongolia have both occurred within homopolymeric regions ([Fig 1](#pone.0206622.g001){ref-type="fig"} and [S2 Fig](#pone.0206622.s004){ref-type="supplementary-material"}). Such regions are prone to slipped-strand mispairing, whereby errors made during DNA replication can result in the insertion or deletion of a nucleotide \[[@pone.0206622.ref023]\]. We postulate that the frameshift mutations in the 33F-1 *wcyO* genes are the result of slipped-strand mispairing events.

This is the first report identifying the *wcyO* acetyltransferase gene in the 33F *cps* locus, and it is also the first report of a naturally occurring frameshifted allele of *wcyO*. The fact that the mutation type and location differ between isolates from Fiji and Mongolia demonstrates this mutation event has occurred on at least two independent occasions. Whether the mutation of *wcyO* is due to selective pressure to inactivate a disadvantageous gene or due to a lack of selective advantage to maintain it remains to be investigated. Previously, mutations have been identified in other pneumococcal capsule acetyltransferase genes including *wciG* \[[@pone.0206622.ref024]\] and *wcjE* \[[@pone.0206622.ref022],[@pone.0206622.ref025],[@pone.0206622.ref026]\]. Serotype 11E, which lacks WcjE-mediated acetylation can evade opsonophagocytosis more efficiently compared to 11A (which possess WcjE-mediated acetylation) \[[@pone.0206622.ref025]\]. Pneumococci expressing 33F capsules, which lack WcjE-mediated acetylation, exhibit enhanced survival during drying compared to serotype 33A (with intact WcjE-mediated acetylation) \[[@pone.0206622.ref027]\]. Laboratory constructed *wciG* mutants in serogroup 33 isolates were more susceptible to opsonophagocytosis, and displayed increased adherence and biofilm formation \[[@pone.0206622.ref027]\]. It is plausible that mutation of *wcyO* in the 33F-1 pneumococci may serve a similar purpose, however this requires further investigation.

Within the 33F-1 *cps* locus we identified 7/15 genes that exhibit higher DNA sequence similarity to homologues from other serotypes rather than 33F. Both *glf* and *wcyO* are similar to sequences from serotypes 34 and 39 (and 33C for *wcyO*) ([Fig 3F and 3G](#pone.0206622.g003){ref-type="fig"}) and *wzg*, *wzh*, *wzd*, *wze* and *wchA* similar to sequences from 33B ([Fig 2A--2E](#pone.0206622.g002){ref-type="fig"}). Recombination of the pneumococcal capsule genes resulting in mosaic *cps* loci such as that of 33F-1 have been reported previously \[[@pone.0206622.ref028],[@pone.0206622.ref029]\]. Alignment of the 33F and 33F-1 *cps* loci support this by showing higher sequence divergence across the *wzg* through to the 5' half of *wchA*, as well as in the second half of *wciG* and the 5'and 3' ends of *glf*, suggesting these may be the recombination sites ([S4 Fig](#pone.0206622.s006){ref-type="supplementary-material"}). Although it is difficult to infer the direction of horizontal transfer of these genes, the mosaic nature of the 33F-1 *cps* locus would suggest an ancestral 33A/F *cps* locus was the recipient of these genes. The 33F-1 isolates in our study were either MLST ST673 or ST13802 ([Table 1](#pone.0206622.t001){ref-type="table"}). Interrogation of the PubMLST database (as of 16th September 2018) shows that ST673 is primarily associated with serotypes 33A/F and not in any *wcyO*-associated serotypes. Likewise, although ST13802 is a novel sequence type described in this study, the most similar MLST profiles (five or more allele matches to ST13802) were either 33A/F serotypes or serotypes that do not possess *wcyO*. These data support the notion that the ancestral strain(s) from which the 33F-1 *cps* locus arose likely possessed a 33A/F *cps* locus. However, it is important to note that the reverse scenario (a *wcyO*-associated serotype acquiring 33A/F *cps* genes) is possible and further genetic analyses are needed.

Interestingly, a serogroup 33 related *cps* locus has been identified in *Streptococcus oralis* subsp. *tigurinus* strain Az_3a \[[@pone.0206622.ref030]\]. This *cps* locus possessed the same genes as the 33F-1 locus with variable DNA identity (\<77% with the 33F-1 *wzg*, *wzh*, *wzd*, *wze*, *wchA* and *wciB* genes, \>96% for *wciC*, *wciD*, *wciE*, *wciF* and *wzy* genes, and 85--90% for *wzx*, *wciG* and *glf* genes, [S2 Table](#pone.0206622.s002){ref-type="supplementary-material"}). The higher DNA identity of 33F-1 *cps* genes with homologues from other pneumococcal serotypes suggests the Az_3a *cps* locus may have evolved independently of the 33F-1 locus. In contrast to 33F-1, the *wcyO* gene in Az_3a is in frame and most similar to the pneumococcal serotype 21 homologue (DNA identity 86.8% with serotype 21 *wcyO* compared to 74.5% with 33F-1 *wcyO*). The existence of a divergent 33F-1 *cps* locus with a functional *wcyO* raises interesting questions around why this gene has been inactivated in 33F-1 pneumococci but remains intact in a non-pneumococcal streptococcal species.

This study describes a novel genetic basis for pneumococcal serotype 33F. Serotype 33F is a replacing serotype in invasive disease following vaccine introduction \[[@pone.0206622.ref005]--[@pone.0206622.ref007]\]. The public health importance of 33F is reflected in that it has been included in two upcoming vaccine formulations (PCV15 and PCV24) \[[@pone.0206622.ref008]\]. In addition, there is increasing popularity in molecular serotyping approaches and it is therefore important to identify genetic variants, which have the potential to impact serotyping results. This is particularly important for the implementation of such methods in LMICs, where there is limited understanding of the pneumococcal *cps* loci. The data gained from this study will be used to update genetic typing tools for more accurate typing of serotype 33F in LMICs.
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###### Quellung serotyping for Statens Serum Institut (SSI) reference strains (33F and 33A) and two representative 33F-1 isolates.
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###### DNA sequence identity of 33F-1 *cps* genes with other serotypes.

Pairwise alignments of each 33F-1 gene with homologues from other serotypes were performed using MUSCLE.
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###### Representative latex agglutination reactions of Statens Serum Institut (SSI) 33F and 33A reference strains, and two representative 33F-1 isolates from this study (PMP1348 and PMP1387).

Latex reagents were prepared using SSI antisera (33b, 33e, 33f, 6a and 20b) as described in the materials and methods. A positive reaction was defined by the presence of clumping and a reduction in background turbidity.
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Click here for additional data file.

###### Sanger sequencing of 33F-1 *wcyO* region from four 33F-1 isolates (PMP1351, PMP1352, PMP1379, PMP1380, PMP1386, PMP1387).

These sequences were aligned to a representative sequence from serotype 34 strain 676/74 (Genbank accession no. CR931703), serotype 39 strain 203/40 (Genbank accession no. CR931711) and representative *wcyO* sequences from serotype 34 and 39 isolates from Fiji using Clustal Omega. Red sequence indicates the 3'end of *glf*, blue indicates *wcyO*, and the highlighted regions denote the frameshift mutation site in the 33F-1 sequences. Identical nucleotides are denoted by an asterisk.
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###### Amino acid alignment of proteins encoded in 33F and 33F-1 *cps* loci.

Identical, conserved and semi-conserved residues are denoted by the symbols '\*', ':' and '.', respectively.
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Click here for additional data file.

###### Nucleotide alignment of 33F and 33F-1 *cps* loci.

Identical nucleotides are noted by '\|' and differences are highlighted by ':'.
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Click here for additional data file.

###### Full maximum likelihood phylogenetic trees of 33F-1 *cps* genes with homologues from all other serotypes.

DNA sequences were aligned using MUSCLE and trees were constructed using the Tamura-Nei model in MEGA 7. Only bootstrap values above 50% are shown.
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